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Abstract Purpose: Activity of histidine decarboxylase, the key enzyme in the synthesis of histamine, has
been shown tobe increased in several types of human tumors.We attempted to establishwhether
the possible involvement of histidine decarboxylase and histamine in colorectal carcinogenesis
might bemediated by the activation of the cyclooxygenase-2 (COX-2) pathway.
Experimental Design: Expression/activity of histidine decarboxylase, histamine content, and
prostaglandin E2 (PGE2) production were analyzed in 33 colorectal cancer samples and in the
HT29, Caco-2, and HCT116 colon cancer cell lines. The effects of histamine, celecoxib, and H1,
H2, and H4 receptor antagonists on COX-2 expression/activity, cell proliferation, and vascular
endothelial growth factor (VEGF) production were assessed in the three colon cancer lines that
showed different constitutive COX-2 expression.
Results:We showed the up-regulationof histidine decarboxylase protein expression and activity
in the tumor specimens when compared with normal colonic mucosa. Histidine decarboxylase
activity and histamine content were also significantly higher inmetastatic tumors than in nonme-
tastatic ones.These variables significantly correlatedwith tumorPGE2 production.Theadministra-
tion of histamine increased COX-2 expression/activity, cell proliferation, andVEGF production in
the COX-2-positive HT29 and Caco-2 cells.Treatment with either H2/H4 receptor antagonists or
celecoxib prevented these effects. Histamine hadno effect onboth the COX-2 pathway andVEGF
production in the COX-2-negative HCT116 cells.
Conclusions: Our data showed that histamine exerts both a proproliferative and a proangio-
genic effect via H2/H4 receptor activation. These effects are likely to be mediated by increasing
COX-2-related PGE2 production in COX-2-expressing colon cancer cells.
Histamine plays a pivotal role in a number of processes,
including inflammation, allergic reaction, gastric acid secre-
tion, and neurotransmission. These different biological effects
are mediated through the activation of specific histamine
membrane receptors (i.e., H1, H2 H3 and H4), which differ in
their tissue expression profiles and functions (reviewed in
ref. 1). The H1 receptor is mainly expressed in the brain,
endothelial cells, and smooth muscle cells and is thought to
play an important role in allergy. The H2 receptor regulates
gastric acid secretion in the stomach. The H3 receptor is
mainly restricted to cells in the central nervous system and
regulates, as a presynaptic autoreceptor, the release of
histamine and neurotransmitters by neurons. The H4 receptor
is a new member of the histamine receptor family and is
predominantly expressed in peripheral blood leukocytes.
However, very little is known about the physiologic role of
H4 receptor.
Histamine levels in cells and tissues are regulated by the
activity of histidine decarboxylase (EC 4.1.1.22) that is the only
enzyme responsible for the generation of histamine from
L-histidine (2). Therefore, histidine decarboxylase can serve as
a specific marker for biosynthesis of histamine. It has been
shown that levels of mRNA encoding histidine decarboxylase,
histidine decarboxylase protein expression, and enzymatic
activity are significantly increased in both experimental and
human tumors, such as melanoma (3, 4), small cell lung carci-
noma (5), breast carcinoma (6), endometrial cancer (7), and
colorectal carcinoma (8). These data suggest that histamine
may be directly involved in tumor development and progres-
sion. However, the most compelling data supporting a poten-
tial role of histamine in carcinogenesis are the results of clinical
Human Cancer Biology
Authors’Affiliations:Departments of 1General Surgery; 2Experimental Pathology
and Oncology; 3Anatomy, Histology, and Forensic Medicine; 4Human Pathology
and Oncology; and 5Preclinical and Clinical Pharmacology, Medical School,
University of Florence, Italy
Received 3/25/05; revised 6/14/05; accepted 7/6/05.
Grant support: Italian Ministry of University, Scientific and Technological
Research,World Cancer Research Found International, Ente Cassa di Risparmio di
Firenze, and Associazione Italiana Ricerca sul Cancro.
The costs of publication of this article were defrayed in part by the payment of page
charges.This article must therefore be hereby marked advertisement in accordance
with18 U.S.C. Section1734 solely to indicate this fact.
Requests for reprints: Fabio Cianchi, Dipartimento di Area Critica Medico-
Chirurgica, Medical School, University of Florence Viale Morgagni 85, 50134
Firenze, Italy. Phone: 3955-427-7566; Fax: 3955-422-0133; E-mail: cianchif@
mail.unifi.it.
F2005 American Association for Cancer Research.
doi:10.1158/1078-0432.CCR-05-0675
www.aacrjournals.org Clin Cancer Res 2005;11(19) October1, 20056807
trials that showed increased survival of gastric and colon cancer
patients after treatment with H2 receptor antagonists, such as
cimetidine or ranitidine (9–12).
It has been reported that histamine may regulate cell
proliferation (13, 14). In particular, histamine has been shown
to stimulate the in vitro and in vivo growth of both melanoma
(15) and gastrointestinal cancer cells and treatment with
cimetidine can reverse these effects (16). Tumor invasion and
metastasis are, clinically, even more relevant than tumor
growth. It is known that these processes are mainly dependent
on the capability of tumor cells to adhere to endothelial cells
and induce new microvessel formation. Cimetidine has been
shown to inhibit HT29 colon cancer cell adhesion to human
umbilical vein endothelial cells by blocking E-selectin expres-
sion (17). Histamine has also been reported to act as an
angiogenic factor (18, 19) and induce vascular endothelial
growth factor (VEGF) production in granulation tissue (20).
However, the possible relationship between histamine and
angiogenesis in cancer has not been investigated yet.
Several lines of evidence have shown that prostaglandin E2
(PGE2), the main product of cyclooxygenase-2 (COX-2)
activity, can promote a number of molecular mechanisms
involved in colorectal carcinogenesis (reviewed in ref. 21), in
particular tumor cell proliferation and angiogenesis (22–25).
The role of histamine in modulating PGE2 production has been
shown in experimental models of inflammation (26, 27). To
our knowledge, the possible interaction between histamine and
COX-2 activity in tumor cells has not been investigated yet.
In the present study, we addressed the hypothesis that
activation of the COX-2 pathway mediates, at least in part,
the possible link between histamine and colorectal cancer. We
determined histidine decarboxylase expression/activity and
histamine content in human colorectal cancer specimens. These
variables were correlated with tumor staging and PGE2
production. We also evaluated the effects of histamine and H1,
H2, and H4 receptor antagonists on COX-2 protein expression/
enzymatic activity, cell proliferation, and VEGF production in
the HT29, Caco-2, and HCT116 colon cancer cell lines that have
different constitutive COX-2 protein expression.
Materials andMethods
Patients and tissue collection. Tissue samples were obtained from 33
patients (15 males and 18 females; median age, 65 years; age range,
46-81 years) who had consecutively undergone surgical resections for
primary sporadic colorectal adenocarcinomas at the Department of
General Surgery, University of Florence, Florence, Italy. All patients
were thoroughly informed about the aims of the study and gave written
consent for the investigation in accordance with the ethical guidelines
of our University. Six tumors were located in the proximal colon (up to
the splenic flexure), 17 in the distal colon, and 10 in the rectum.
Twenty-seven tumors were classified as adenocarcinomas and six
tumors were classified as mucinous carcinomas (when >50% of the
tumor volume was composed of mucin). Adenocarcinomas were
classified as well differentiated (n = 0), moderately differentiated (n =
24), and poorly differentiated (n = 3). Tumors were classified into four
stages according to the American Joint Committee on Cancer staging
system (28): stage I (T1-T2, N0, and M0; n = 3), stage II (T3-T4, N0,
and M0; n = 16), stage III (any T, N1-2, M0; n = 12), and stage IV (any
T and any N and M1; n = 2).
Cancer tissue (from the edge of the tumor) and adjacent normal
mucosa (at least 10 cm from the tumor) were excised from each surgical
specimen. The samples were washed in PBS. They were flash-frozen in
liquid nitrogen for reverse-transcriptase PCR, frozen at 80jC for
Western blot analysis, and frozen at 20jC for histidine decarboxylase
activity and histamine and PGE2 production evaluation until process-
ing. Other samples were fixed in 4% formaldehyde and embedded in
paraffin for immunohistochemical analysis.
Cell culture and drugs. Experiments were done on the HT29,
Caco-2, and HCT116 human colon cancer cell lines and on the HL-60
human leukemia cell line. The HT29 and HCT116 cells were a gift from
Dr. Claudia Casini Raggi (Department of Clinical Physiopathology,
University of Florence). The Caco-2 and HL-60 cells were purchased
from Interlab Cell Line Collection (Genoa, Italy). Both HT29 and
Caco-2 cells constitutively express COX-2 protein (29, 30), whereas the
HCT116 cells do not express COX-2 (29). The HL-60 cells constitutively
express a high level of the H1, H2, and H4 receptors (31, 32). These cells
served as a positive control. The cells were cultured as previously
described (25). Histamine dihydrochloride, the histamine H1 receptor
antagonist mepyramine maleate, and the histamine H2 receptor
antagonist zolantidine were purchased from R.B.I. (Natick, MA). The
H4 receptor antagonist JNJ 7777120 was supplied by Johnson &
Johnson Pharmaceutical Research and Development LLC (San Diego,
CA). The selective COX-2 inhibitor celecoxib was provided by
Monsanto (St. Louis, MO).
Histidine decarboxylase immunostaining. Four-micrometer-thick
sections were cut from the formalin-fixed and paraffin-embedded
tissue blocks and processed as previously described (24). Immuno-
histochemical staining was done using the streptavidin-biotin perox-
ydase method. A rabbit polyclonal antibody (Euro-Diagnostica AB,
Malmo¨, Sweden) for histidine decarboxylase at 1:1,000 dilution at
4jC overnight was used. Positive control for histidine decarboxylase
immunostaining included sections of normal human gastric mucosa
of the fundus. Tissue sections, treated with nonimmune rabbit serum
in place of the primary antibodies were used as negative controls.
Observations were carried out with a Reichert-Jung Microstar IV light
microscope (Cambridge Instruments, Buffalo, NY) and registered with
a video camera (WPI, Sarasota, FL) interfaced with a personal
computer through a Matrox Marvel G400-TV digitizing card (Matrox
Graphics, Dorval, Canada).
Two pathologists (L.M. and D.B.) independently evaluated the
immunostained specimens. The extent of histidine decarboxylase
immunostaining was recorded semiquantitatively using a three-grade
system, based on the percentage of stained tumor epithelial cells: grade
0, 1% to 20%; grade 1, 21% to 70%; grade 2, >70%.
Assay for histidine decarboxylase activity. Histidine decarboxylase
activity was assayed by measuring [14C]CO2 evolved from L-[carbox-
yl-14C]-histidine (46 mCi mmol1) according to the method described
previously (33). Determinations were done in quintuplicate. The
enzyme activity is expressed as ng of histamine formed per either Ag
or mg of protein per hour in the tissue samples and in the cells,
respectively.
Histamine content determination. Histamine content was assessed
fluorimetrically in tissue specimens and in the cells using the method
of Sho¨re et al. (34) as modified by Kremzner and Wilson (35).
Histamine was extracted from tissue and cell homogenates as
previously reported (36) and derivatized to a fluorogenic compound
with ortho -phthaldialdehyde. Fluorescence was monitored at the
emission/excitation ratio of 365:455 nm using a spectrofluorimeter
Shimadzu RF 5000 (Kyoto, Japan). The detection limit of the method is
10 pg histamine base mL1. The authenticity of histamine in tissue
specimens and in the cells was shown by recording the excitation and
emission fluorescent spectra. Incubation of extracted tissue samples
with histaminase (1 mg mL1 from porcine kidney) selectively removed
the histamine peak, confirming its identity. Determinations were done
in quintuplicate. Histamine values were expressed as ng per either Ag or
mg of protein in the tissue samples and the cells, respectively.
Prostaglandin E2 measurement. Normal mucosa and tumor samples
were processed as described previously (24). Supernatants of the HT29,
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Caco-2, and HCT116 cells were prepared according to the method
described previously (25). Drugs (1 Amol/L mepyramine, zolantidine,
JNJ 7777120, and celecoxib) were added 30 minutes before histamine
(1 Amol/L) administration. After 24 hours of incubation, the super-
natants were collected. Supernatants (500 mL) of tissue homogenates
and 100 AL supernatants of the cells were used for PGE2 determination
using a competitive enzyme immunoassay kit (Cayman Chemical Co.,
Ann Arbor, MI) according to the method described by Pradelles et al.
(37). Protein concentration in the tissue samples and in the cells was
determined according to the method described by Lowry et al. (38).
Bovine serum albumin was used as the standard. Determinations were
done in quintuplicate. PGE2 values were expressed as Ag per mg protein
in the tissue samples and pg per Ag protein in the cells.
Reverse-transcriptase PCR. RT-PCR was done on total RNA extracted
from tissue samples and cells using the RNAeasy Kit (Qiagen, Hilden,
Germany). Two micrograms of total RNA were retrotranscribed to
cDNA with the Improm-II Reverse Transcriptase kit (Promega,
Madison, WI) and amplified with the following primers for the human
H1, H2, and H4 histamine receptor subtypes: 5V-AAGTCACCATCC-
CAAACCCCCAAG-3V/5V-TCAGGCCCTGCTCATCTGTCTTGA-3V for the
H1 receptor, 5V-AGGAACGAGACCAGCAAGGGCAAT-3V/5V-GGTGG-
CTGCCTTCCAGGAGCTAAT-3Vfor the H2 receptor, and 5V-CCGTTTGG-
GTGCTGGCCTTCTTAG-3V/5V-TCCACCACCCTGTTGCTGCTGTA-3V for
the H4 receptor. The sizes of the three RT-PCR products were 195,
197, and 203 bp, respectively. A glyceraldehyde-3-phosphate dehydro-
genase 196-bp PCR product was obtained using the following primer
pair: 5V-CCATGGAGAAGGCTGGGG-3V/5V-CAAAGTTGTCATGGAT-
GACC-3V. Amplification of cDNA was done with the following profiles:
95jC for 15 minutes followed by 40 cycles at 95jC for 30 seconds,
63jC for 30 seconds, and 72jC for 30 seconds for histamine receptors
and 95jC for 2 minutes followed by 30 cycles at 95jC for 30 seconds,
58jC for 30 seconds, and 72jC for 40 seconds for glyceraldehyde-3-
phosphate dehydrogenase. The HL-60 cells served as a positive control
for histamine receptors.
Western blot analysis. Total proteins from tumor tissue and the
corresponding normal mucosa were obtained as described previously
(24). The HT29, Caco-2, and HCT116 cells were grown to subcon-
fluence and starved for 24 hours in 0.1% FCS-supplemented medium.
After incubation with 1 Amol/L histamine in the absence or presence
of drugs for indicated times, cells were washed in PBS and lysed with
radioimmunoprecipitation assay buffer [20 mmol/L Tris-HCl (pH 7.1)
150 mmol/L NaCl, 5 mmol/L EDTA, 2% SDS, 0.00125% bromophe-
nol blue, 5% h-mercaptoethanol]. Seventy micrograms of total
proteins, as evaluated by bicinchoninic acid assay, from tissue or
cultured cells were subjected to Western blotting and immunoblotting
analysis as previously described (25). The loading and transfer of
equal amounts of proteins were ascertained by either reblotting the
membrane with an anti-actin antibody for tissue samples or staining
the membrane with Ponceau S for cell samples. Primary antibodies
used were anti-histidine decarboxylase rabbit polyclonal antibody
(1:1,000; Euro-Diagnostica), anti-COX-2 goat polyclonal antibody
(1:1,000; Santa Cruz Biotechnology Inc., Santa Cruz, CA), anti-VEGF
mouse monoclonal antibody (1:1,000, Santa Cruz Biotechnology),
and goat polyclonal anti-actin antibody (1:1,000, Santa Cruz
Biotechnology). Binding of each primary antibody was determined
by addition of suitable peroxidase-conjugated secondary antibodies
(1:5,000; Amersham, Braunschweig, Germany).
Cell viability assay. The 3-(4,5-dimethylthiazol-2yl)-2,5-diphenylte-
trazolium bromide assay was done to determine the cytotoxicity of
mepyramine, zolantidine, JNJ 7777120, and celecoxib against the
HT29, Caco-2, and HCT116 cells according to the method previously
described (25).
Cell proliferation assay. HT29, Caco-2, and HCT116 cell prolifer-
ation was determined by the [3H]thymidine incorporation assay
according to the method previously described (25). The experiments
were done in quintuplicate, and the values were expressed as dpm per
well.
Quantification of vascular endothelial growth factor production. An
ELISA method was used to quantify the secreted VEGF in the culture
medium of the HT29, Caco-2, and HCT116 cells according to the
method previously described (25). Determinations were done in
quintuplicate. VEGF values were expressed as pg per Ag protein.
Statistical analysis. Histidine decarboxylase activity, incorporation
of [3H]thymidine, and histamine, PGE2, and VEGF levels were
expressed as mean values F SE. The relationships among histidine
decarboxylase activity, histamine content, and PGE2 production were
evaluated using the Spearman correlation coefficients (r s). Differences
in histidine decarboxylase activity and histamine content in tumor and
normal mucosa specimens and in tumors with and without metastases
were analyzed using the Mann-Whitney test. [3H]thymidine incorpo-
ration, PGE2, levels and VEGF levels in the cells were compared using
the paired-value Wilcoxon test or the Mann-Whitney test, as appropri-
ate. Statistical analysis was done using Stata Statistic Software (release
5.0; Stata Corp., College Station, TX). All of the Ps resulted from the use
of two-sided statistical tests; Ps < 0.05 were considered statistically
significant.
Results
Histidine decarboxylase expression and activity in human
colorectal cancer and colon cancer cells. Most of the tumors
showed extensive immunostaining for histidine decarboxylase
protein: 10 tumors (30.3%) were grade 0, 11 (33.3%) were
grade 1, and 12 (36.4%) were grade 2. Histidine decarboxylase
was found mainly in the tumor epithelial cells (Fig. 1A). There
was also some staining of the inflammatory mononuclear cells
(i.e., histamine-producing mast cells and macrophages) that
infiltrate the tumors. However, the extent of histidine decar-
boxylase expression by nonepithelial interstitial cells never
exceeded that found in the corresponding tumor tissue.
Histidine decarboxylase staining was not detectable in normal
colon epithelial cells (Fig. 1B). Histidine decarboxylase
expression was occasionally found in the histaminergic enter-
oendocrine cells (i.e., enterochromaffin-like cells) and in
nonepithelial interstitial cells of normal mucosa.
Western blot analysis confirmed the overexpression of
histidine decarboxylase protein that had been detected by
immunohistochemistry. A higher amount of protein was found
in the neoplastic tissue when compared with the corresponding
normal mucosa (Fig. 1C). The main form of histidine
decarboxylase protein detected in our tumor specimens had a
molecular mass of 74 kDa (Fig. 1C). Low levels of histidine
decarboxylase protein were detected in normal mucosa of 25%
to 30% of the specimens. This may reflect the abovementioned
enterochromaffin-like cell and nonepithelial cell histidine
decarboxylase expression. However, the level of histidine
decarboxylase in normal mucosa never exceeded that found
in the neoplastic tissue. Histidine decarboxylase protein
expression was also found in the HT29, Caco-2, and HCT116
colon cancer cells. Histidine decarboxylases (74- and 54 kDa)
gave bands of similar intensity (Fig. 1D).
Histidine decarboxylase activity and histamine content
were significantly higher in the tumor specimens than in the
corresponding normal mucosa (42.7 F 2.4 versus 15.8 F
1.0 ng of histamine/Ag protein/h, P = 0.003 and 28.1 F 2.4
versus 0.7 F 0.3 ng/Ag protein, P < 0.0001, respectively; Fig. 1E
and F). These variables were also significantly higher in tumors
with lymph node and/or distant metastases (stages III-IV) than
in those without any metastases (stages I-II) (51.51 F 3.1
versus 35.1 F 2.7 ng of histamine/Ag protein/h, P < 0.001 and
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35.0 F 3.1 versus 22.4 F 2.0 ng/Ag protein, P = 0.03,
respectively; Fig. 1E and F). PGE2 production was significantly
higher in the tumor specimens than in the corresponding
normal mucosa (10.3 F 2.0 versus 3.1 F 0.5 Ag/mg protein,
P < 0.0001). It was also significantly higher in tumors with lymph
node and/or distant metastases (stages III-IV) than in those
without any metastases (stages I-II) (11.5 F 3.0 versus 7.8 F
1.8 Ag/mg protein, P = 0.02). Histidine decarboxylase activity
and histamine content were significantly correlated with PGE2
production (rs = 0.42, P = 0.01 and r s = 0.30, P = 0.04,
respectively; Fig. 1G and H).
Histidine decarboxylase activity values in the HT29, Caco-2,
and HCT116 cells were 11.5F 5.7, 9.7 F 6.3 and 15.3F 4.5 ng
of histamine/mg protein/h, respectively. Total histamine levels
(in the cells plus supernatant) were 2.7 F 0.9, 3.5 F 0.2, and
8.4 F 1.2 ng/mg protein in the HT29, Caco-2, and HCT116
cells, respectively. Our in vitro results confirmed that histamine
could be synthesized de novo by colon cancer cells. To confirm
the authenticity of histidine decarboxylase activity, we verified
the suppression of the histamine forming capacity in the
cells by preincubating some cell extracts with 105 mol/L
a-fluoromethylhistidine, a selective inhibitor of histidine
decarboxylase (data not shown).
Expression of H1, H2, and H4 receptor mRNA in human
colorectal cancer and colon cancer cells. RT-PCR detected mRNA
levels for H1, H2, and H4 receptors in both colorectal cancer
specimens and adjacent normal colonic mucosa. (Fig. 2A).
mRNA of the three types of receptor was also detected in the
COX-2-positive HT29 and Caco-2 cells and in the COX-2-
negative HCT116 cells (Fig. 2B and C, respectively).
Effects of histamine receptor antagonists and celecoxib on cell
viability. Drug cytotoxicity was quantified using the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay.
Mepyramine, zolantidine, JNJ 7777120, and celecoxib had
similar cytotoxic effects against the HT29 and Caco-2 cells with
significant loss of viability at concentrations of z10 Amol/L
(data not shown). A significant loss in cell viability in the
HCT116 cells was observed after treatment with mepyramine,
zolantidine, JNJ 7777120, or celecoxib concentrations of z25
Amol/L (data not shown). Subsequent experiments were done
using noncytotoxic doses of both histamine receptor antago-
nists and celecoxib (1 Amol/L).
Fig. 1. Histidine decarboxylase (HDC)
protein expression and activity in
human colorectal cancer specimens.
A , immunohistochemical analysis showed
that tumor epithelial cells were positive
for histidine decarboxylase staining.
Hematoxylin counterstain (original
magnification,25). B, histidine
decarboxylase expressionwas not
detectable in the normal colon epithelial
cells. Hematoxylin counterstain (original
magnification,25). C,Western blot
analysis. Expression of histidine
decarboxylase in representative paired
adenocarcinoma and adjacent normal
mucosa from three patients. A higher
amount of histidine decarboxylase was
found in the neoplastic tissue than in the
normal mucosa. Histidine decarboxylase
(74 kDa) was the main form detected in the
colorectal cancer specimens. Human
gastric mucosa of the fundus served as a
positive control for histidine decarboxylase.
Samples were normalized for protein
loading (70 Ag) by reblotting the
membrane-boundproteinwith an anti-actin
antibody. Abbreviations:T, tumor;
N, normalmucosa.D, Westernblot analysis.
Expression of histidine decarboxylase in the
HT29, Caco-2, and HCT116 colon cancer
cells. Histidine decarboxylases (74- and
54 kDa) gave bands of equal intensity.
Samples were normalized for protein
loading (70 Ag) by Ponceau S staining of
the membrane-bound protein. E and F,
histidine decarboxylase activity and
histamine content were significantly higher
in the 33 tumor samples than in the
corresponding normal mucosa specimens.
They were also significantly higher in the19
metastatic (stages III and IV) tumors than in
the14 nonmetastatic (stages I and II) ones.
Columns, means of five determinations;
bars, SE.G andH, histidine decarboxylase
activity and histamine content were
significantly correlated with PGE2
production.
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Effects of histamine on cyclooxygenase-2 expression and activity
in the HT29, Caco-2, and HCT116 colon cancer cells. Western
blot analysis showed a significant basal COX-2 expression in
the HT29 cells (Fig. 3A and D), whereas very low basal levels
were present in the Caco-2 cells (Fig. 3B and E). No detectable
basal COX-2 expression was present in the HCT116 cells
(Fig. 3C). Treatment of the HT29 and Caco-2 cells with
histamine increased COX-2 protein expression in a time-
dependent manner (Fig. 3A and B). COX-2 protein levels
reached a maximum at 18 hours in both cell lines and then
declined (Fig. 3A and B). Treatment of the HCT116 cells with
histamine did not cause any increase in COX-2 expression
(Fig. 3C). To determine which subtype/s of histamine receptor
is/are involved in COX-2 activation, the HT29 and Caco-2 cells
were treated with histamine in the presence of selective
antagonists to H1 (mepyramine), H2 (zolantidine), or H4 (JNJ
7777120). Zolantidine or JNJ 7777120 but not mepyramine
prevented COX-2 induction by histamine (Fig. 3D and E).
Basal PGE2 production did not significantly differ among the
three cell lines. After incubation of the cells with histamine, we
found a significant increase in PGE2 concentrations in the
supernatants of the HT29 and Caco-2 cells but not in those of
the HCT116 cells (Table 1). The administration of celecoxib
significantly reduced histamine-mediated PGE2 production in
the HT29 and Caco-2 cells (Table 1). This finding suggests that
COX-2 was the main source of PGE2 after histamine treatment.
The administration of zolantidine or JNJ 7777120 significantly
reduced the histamine-stimulated production of PGE2 (Table 1).
Mepyramine failed to affect PGE2 levels after histamine
administration (Table 1). Combination treatment with zolan-
tidine and JNJ 7777120 determined an additive effect in
reducing histamine-mediated increase in PGE2 production
(Table 1).
Effects of histamine on HT29, Caco-2, and HCT116 cell
proliferation. We examined the effect of histamine on the
proliferation of the HT29, Caco-2, and HCT116 cells by
measuring the incorporation of [3H]thymidine to assess DNA
synthesis. Basal proliferation did not differ among the three cell
lines and it was not affected by treatment with mepyramine,
zolantidine, JNJ 7777120, or celecoxib (Fig. 4). The adminis-
tration of histamine stimulated cell proliferation in all cell lines
(Fig. 4). The addition of mepyramine did not affect the
proliferative response of the cells to histamine (Fig. 4). On the
contrary, the histamine-induced stimulation of HT29, Caco-2,
and HCT116 cell proliferation was significantly antagonized by
the H2 and H4 receptor antagonists zolantidine and JNJ
7777120, respectively. Treatment with the COX-2 inhibitor
celecoxib suppressed the growth-promoting effect of histamine
in the HT29 and Caco-2 cells, but it had no effect in
the HCT116 cells (Fig. 4). Combination treatment with zolan-
tidine and JNJ 7777120 determined an additive effect in redu-
cing histamine-stimulated proliferation in the three cell lines
(Fig. 4).
Effects of histamine on vascular endothelial growth factor levels
in the HT29, Caco-2, and HCT116 colon cancer cells. To
examine the effect of histamine on tumor angiogenesis, we
evaluated VEGF production in the HT29, Caco-2, and HCT116
cells. Western blot analysis showed basal VEGF expression in
the HT29 and HCT116 cells (Fig. 5A and C), whereas no
detectable basal signal was present in the Caco-2 cells (Fig. 5B).
Treatment of the HT29 and Caco-2 cells with histamine
increased VEGF protein levels in a time-dependent manner
with a maximum at 18 and 24 hours in the two cell lines,
respectively (Fig. 5A and B). Treatment of the HCT116 cells
with histamine did not cause any increase in VEGF expression
(Fig. 5C). Histamine-mediated VEGF induction in the HT29
and Caco-2 cells was prevented by the administration of
zolantidine, JNJ 7777120, or celecoxib (Fig. 5D and E), whereas
mepyramine had no effect (Fig. 5D and E).
Quantitative determination of VEGF levels confirmed West-
ern blot analysis results. Basal VEGF production was signifi-
cantly higher in the HCT116 cells than in HT29 (734.1 F 31.5
versus 604.5 F 23.4 pg/Ag protein, P = 0.03) and Caco-2 ones
(734.1 F 31.5 versus 450.7 F 12.5 pg/Ag protein, P = 0.02).
Treatment of the cells with histamine led to a significant
increase in VEGF levels in the HT29 and Caco-2 cells, whereas
Fig. 2. RT-PCR. A , mRNA levels for H1, H2, and H4 receptors were detected in
tumor tissue and in corresponding normal colonmucosa. B and C, mRNA for the
three histamine receptor subtypes was also found in both the COX-2-positive HT29
and Caco-2 human colon cancer cell lines and the COX-2-negative HCT116 human
colon cancer cell line.The HL60 human leukemia cell linewas used a positive control
for H1, H2, and H4 receptors.The housekeeping geneGAPDH was used as an
internal control.
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the same treatment had no effect in the HCT116 cells (Table 1).
The administration of zolantidine, JNJ 7777120, or celecoxib
to the HT29 and Caco-2 cells significantly reduced the
histamine-stimulated production of VEGF (Table 1). The
administration of mepyramine did not affect VEGF levels
(Table 1). Combination treatment with zolantidine and JNJ
7777120 had an additive effect on reducing the histamine-
mediated increase in VEGF production (Table 1).
Discussion
Although the hypothesis that histamine might be involved in
carcinogenesis was proposed in the 1960s (39), it still remains
under discussion today. Accumulated evidence points to a
direct relationship between up-regulation of histidine decar-
boxylase activity and growth of several types of human tumors
(3–7). As regards colorectal cancer, Garcia-Caballero et al. (8)
have shown a significantly higher histidine decarboxylase
activity in 10 tumor specimens than in the corresponding
normal colon mucosa. More recently, Boe´r et al. (40) have
shown a strong immunoreactivity for histidine decarboxylase in
both adenomatous polyps and colorectal cancer specimens.
Our results showed a sustained histidine decarboxylase protein
expression and activity in both human colorectal tumor spe-
cimens and three colon cancer cell lines (i.e., HT29, Caco-2,
and HCT116). We also showed the expression of H1, H2, and
Table 1. Effects of histamine, celecoxib, and H1, H2, and H4 receptor antagonists on PGE2 (pg/Ag protein) andVEGF
(pg/Ag protein) production in the HT29, Caco-2, and HCT116 colon cancer cell lines
Drugs HT29 cell line Caco-2 cell line HCT116 cell line
PGE2
production
VEGF
production
PGE2
production
VEGF
production
PGE2
production
VEGF
production
None 19.8F 1.8 604.5F 23.4 12.5F1.7 450.7F12.5 16.9F 2.0 734.1F31.5
Mepyramine (1 Amol/L) 20.3F 0.9 795.0F 19.9 10.4F 0.4 447.0F 13.7 18.9F 0.2 731.2F 54.4
Zolantidine (1 Amol/L) 18.3F 0.7 640.4F 35.4 12.1F2.7 462.7F16.3 16.0F 3.1 708.3F 31.5
JNJ 7777120 (1 Amol/L) 18.4F 2.1 703.3F 31.3 11.8F 2.8 440.1F22.7 20.0F 0.4 822.5F 36.8
Celecoxib (1 Amol/L) 18.9F 0.8 712.0F 36.7 12.8F 2.3 454.4F 24.2 18.4 F 1.1 748.2 F 71.4
Histamine (1 Amol/L) 118.7F2.86* 1446.7F 59.8* 136.7F2.6* 1043.2F 65.5* 19.1F 0.9 831.1F14.2
Histamine + celecoxib 71.8F 1.2c 894.3F 14.3c 81.7F2.8c 667.0F 36.4c F F
Histamine +mepyramine 109.4F 2.0 1165.9F 27.2 137.9F 1.7 1004.8F 93.6 F F
Histamine + zolantidine 52.6F 1.1c 789.9F 31.2c 104.6F 3.9c 834.4F19.3c F F
Histamine + JNJ 7777120 63.1F 2.5c 862.1F5.7c 115.4F 4.3c 838.9F 9.2c F F
Histamine + zolantidine + JNJ 7777120 40.6F1.0c 709.9F 21.3c 93.4F 4.1c 699.4F 27.6c F F
NOTE: Results are expressed as meansF SE of five determinations per treatment.
*P < 0.05, significant increase compared with unstimulated cells (Wilcoxon test).
cP < 0.05, significant inhibition compared with histamine treatment (Wilcoxon test).
Fig. 3. Western blot analysis. Effects of
histamine on COX-2 protein expression in
the HT29, Caco-2, and HCT116 colon
cancer cells.A and B, treatment with
histamine (1 Amol/L) increased COX-2
protein levels in a time-dependentmanner in
the HT29 and Caco-2 cells. Up-regulation
of COX-2 was maximum after18 hours.
C, the same treatment had no effect in the
HCT116 cells.D and E , the H2 receptor
antagonist zolantidine (1 Amol/L) and
the H4 receptor antagonistJNJ 7777120
(1 Amol/L) prevented the histamine-
induced overexpression of COX-2 in the
HT29 and Caco-2 cells.The H1receptor
antagonist mepyramine had no effect on
histamine-induced COX-2 overexpression.
Samples were normalized for protein
loading (70 Ag) by Ponceau S staining of
the membrane-bound protein.
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H4 receptor mRNA in the same tumor samples and cells. The
coexistence of endogenously produced histamine and its
specific membrane receptors strongly suggests an autocrine
loop for histamine in colorectal cancer carcinogenesis. Immu-
noblot analysis showed that the main form of histidine
decarboxylase protein detected in our cancer specimens had a
molecular mass of 74 kDa. These findings are in contrast with
those reported by previously published studies on the correla-
tion between the immunoreactive forms of histidine decarbox-
ylase and its enzymatic activity in mice and rats. It has been
shown that the 74-kDa histidine decarboxylase is an enzymat-
ically inactive proenzyme, which has to be activated by
posttranslational processing into the 54-kDa subunit form
(41, 42). Nevertheless, Yatsunami et al. (43) have shown that
74- and 54-kDa histidine decarboxylases exhibit equivalent
histamine-synthesizing activity in humans. These authors
hypothesized that the activity of 74-kDa histidine decarbox-
ylases might differ in humans, mice, and rats, because their
COOH-terminal regions are not completely homologous. This
may explain the association between high levels of histidine
decarboxylase activity and up-regulation of the 74-kDa histidine
decarboxylase in our colorectal cancer specimens. Unlike with
tumor tissue, we found that both the 54- and 74-kDa histidine
decarboxylases are equally represented in all three colon cancer
cell lines. Because multiple forms of histidine decarboxylase
have been shown to be generated by tissue- or cell-specific
posttranslational processing (42, 44), it might be hypothesized
that different processing pathways are responsible for the
different expression of the 54-kDa subunit form in either the
tumor tissue or the colon cancer cell lines.
Our study showed that high levels of histidine decarboxylase
activity and histamine content were correlated with the
presence of lymph node and/or distant metastases in colorectal
cancer. Interestingly, we also found a significant correlation
between these variables and tumor PGE2 production. A large
body of experimental evidence has shown the close involve-
ment of COX-2 activity and thus PGE2 production in tumor
proliferation and progression (reviewed in ref. 21). Collectively,
our data strongly suggest a role for endogenously synthesized
histamine in the acquisition of an invasive and metastatic
phenotype of tumor cells. However, the specific mechanisms by
which histidine decarboxylase and histamine are involved in
cancer progression are still unknown.
We showed for the first time that exogenous histamine could
increase the expression of COX-2 protein in the HT29 and
Caco-2 human colon cancer cells. Results from RT-PCR
indicated that H1, H2, and H4 receptor genes were expressed
in both cell lines. However, only the selective H2 receptor
antagonist zolantidine and the selective H4 receptor antagonist
JNJ 7777120 prevented histamine-induced COX-2 overexpres-
sion, whereas the selective H1 receptor antagonist mepyramine
did not have this suppressive effect. Therefore, activation of the
H2 and H4 receptors is likely to mediate COX-2 overexpression
by histamine in the HT29 and Caco-2 cells. Interestingly, there
was no observable effect of histamine on COX-2 protein levels in
the HCT116 colon cancer cells, although these cells expressed
H1, H2, and H4 receptors. Because it has been reported that the
HCT116 cells do not constitutively express COX-2, it might be
hypothesized that histamine-mediated COX-2 regulation may
depend on signaling pathways that are already active just at the
basal levels in colon cancer cells.
We also showed that COX-2 induction by histamine resulted
in a sustained enhancement of COX-2 enzymatic activity. The
administration of exogenous histamine to the HT29 and Caco-
2 cells determined an increase in PGE2 production. The
selective inhibition of COX-2 by celecoxib significantly reduced
the histamine-induced production of PGE2. This finding
suggests that COX-2 was the main source of PGE2 after
treatment with histamine. The increase in COX-2 activity was
prevented by treatment with zolantidine and JNJ 7777120,
given alone or in combination, whereas mepyramine had no
suppressive effect. This finding confirmed that only H2 and H4
receptors are functionally involved in the histamine-stimulated
COX-2 activation and PGE2 production. According to Western
blot analysis results, histamine could not increase PGE2
production in the HCT116 cells.
Previous studies showed that concentrations of exogenous
histamine between 106 and 108 mol/L produce a stimulatory
effect on the growth of both melanoma (4, 15) and gastroin-
testinal cancer cells (16, 45). Moreover, cimetidine and other H2
receptor antagonists have been shown to prevent histamine-
mediated increase in tumor cell proliferation but not affect the
basal growth of the same cells in the absence of histamine (16,
45, 46). Our results confirmed the effect of 1 Amol/L exogenous
histamine in stimulating proliferation of the HT29, Caco-2, and
HCT116 cells. We found that both zolantidine and JNJ 7777120
prevented the cell growth–promoting activity of histamine in
the three cell lines, whereas mepyramine had no effect on the
histamine-induced increase in tumor cell proliferation. We also
showed that zolantidine and JNJ 7777120 did not significantly
affect the basal growth of the cells. It is likely that the histamine
levels produced by the cells under our assay conditions are not
effective in sustaining basal cell proliferation.
Fig. 4. Effects of histamine onHT29, Caco-2, andHCT116 cell proliferation
evaluatedby [3H]thymidine incorporation. Basal proliferationdidnot differ among
the three cell lines and it was not affectedby treatment withmepyramine (1 Amol/L),
zolantidine (1 Amol/L), JNJ 7777120 (1 Amol/L), or celecoxib (1 Amol/L).The
administrationofhistamine (1 Amol/L) determineda stimulationof cellproliferationin
the three cell lines.Mepyramine hadno effect onhistamine-induced increase in cell
proliferation, whereas zolantidine andJNJ7777120 prevented the proproliferative
effect of histamine in the three cell lines. Celecoxib inhibited the growth-promoting
effect of histamine in theHT29 andCaco-2 cells, but it hadno effect in theHCT116
cells. Combination treatment with zolantidine andJNJ 7777120 determined an
additive effect in reducinghistamine-stimulated proliferation in the three cell
lines.Columns, means of five different experiments; bars, SE. [3H]thymidine
incorporationwas expressed as dpmper well. *,P < 0.05, significant increase
comparedwithunstimulated cells.#,P < 0.05, significant inhibition comparedwith
histamine treatment.
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Interestingly, we showed that the proproliferative effect of
histamine was inhibited by celecoxib in the HT29 and Caco-2
but not in the HCT116 cells. Collectively, our findings strongly
suggest that histamine is involved in colon cancer cell
proliferation via activation of both H2 and H4 receptors.
Moreover, it is most likely that histamine exerts its proprolifer-
ative effect mainly through the up-regulation of COX-2 activity
in those cancer cells that constitutively express this enzyme,
whereas other mechanisms independent of the COX-2 pathway
may be involved in the COX-2 negative cells. One possible
mechanism by which histamine can directly lead to cell
proliferation has been proposed by Wang et al. (14). These
authors have shown that activation of human H2 receptor
stimulates the growth of HEK-293 cells through the histamine-
induced transcriptional activation of the proto-oncogene c-fos .
Another mechanism potentially involved in the tumor-
promoting effect of histamine is stimulation of tumor
angiogenesis. Histamine has been reported to be a potent
proangiogenic factor in some inflammatory models (39, 47).
Ghosh et al. (20) have shown that histamine contributes to
VEGF protein overexpression and angiogenesis in the carra-
geenin-induced granulation tissue in rats via the H2 receptor–
cyclic AMP-protein kinase A pathway. Moreover, the H2
receptor antagonists cimetidine and roxatidine have been
found to exert their suppressive effect on growth of Colon 38
tumor cell implants in mice by inhibiting VEGF protein
expression and thus reducing tumor vascularization (48). Our
findings showed that treatment of the COX-2-positive HT29
and Caco-2 cells with histamine determined a significant
increase in VEGF levels and this effect was suppressed by the
administration of zolantidine, JNJ 7777120, or celecoxib. On
the contrary, no increase in VEGF levels was found in the COX-
2-negative HCT116 cells after treatment with histamine.
Collectively, these findings suggest that histamine-mediated
increase in VEGF production mainly depends on whether
histamine can also contemporarily up-regulate the COX-2
pathway via H2/H4 receptor activation in the same cancer cells.
Because PGE2 is known to be a potent stimulator of VEGF
release (23, 25), we concluded that enhancement of COX-2-
related PGE2 production may play a prominent role in
mediating the proangiogenic effect of histamine in human
colorectal cancer.
In conclusion, we showed that up-regulation of histidine
decarboxylase activity was correlated with tumor progression
(i.e., the presence of lymph node and/or distant metastases) in
human colorectal cancer. The present study is the first to show a
novel role of histamine in activating the COX-2 pathway via H2
and H4 receptors in COX-2-expressing colon cancer cells. It is
likely that COX-2-related PGE2 production acts as one of the
most important mediators of the proproliferative and proan-
giogenic effects of histamine in colorectal tumors. Collectively,
these data point to the dual inhibition of the histidine
decarboxylase and COX-2 pathways as a possible therapeutic
tool in the treatment of colorectal cancer.
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